If you need more lookups,
subscriptions start at $34 USD/month.
Robert Schaub Location
Cambridge, MA, US
Robert Schaub Work
Vice President of Preclinical Development @ (January 2018 - Present)
Consultant @ Preclinical Development (September 2017 - Present)
Chief Scientific Officer @ AkiraBio (August 2021 - October 2024)
Head R and D @ Enumeral Biomedical Holdings, Inc. (September 2016 - September 2017)
CSO @ NKT Therapeutics Inc. (December 2011 - January 2016)
Consultant @ Hematology and Preclinical R&D (June 2011 - November 2011)
Senior Vice President Research and Development @ Archemix (September 2009 - June 2011)
Vice President @ Archemix (August 2006 - September 2009)
Director to Asst Vice President @ Genetics Institute/Wyeth Research (February 1990 - August 2006)
Principal to Senior Scientist @ Upjohn Company (December 1981 - February 1990)
Asst to Assoc Professor (Tenured) @ (April 1977 - November 1981)
Robert Schaub Education
Temple University - Lewis Katz School of Medicine
Postdoc (NIH )
1975-1977
Washington State University
Postdoc (Heart Association )
1973-1975
Washington State University
Ph.D. (Physiology)
1970-1973
University of Nevada-Las Vegas
B.S. (Biology/Chemistry)
1966-1970
Robert Schaub Skills
Fundraising
Life Sciences
Commercial Lending
Management Consulting
Statistics
Microsoft Excel
Small Business Lending
Science
Communication
Equities
Robert Schaub Summary
Robert Schaub, based in Cambridge, MA, US, is currently a Vice President of Preclinical Development at Aquinnah Pharmaceuticals. Robert Schaub brings experience from previous roles at Preclinical Development, AkiraBio, Enumeral Biomedical Holdings, Inc. and NKT Therapeutics Inc.. Robert Schaub holds a 1975 - 1977 Postdoc in NIH @ Temple University - Lewis Katz School of Medicine. With a robust skill set that includes Fundraising, Life Sciences, Commercial Lending, Management Consulting, Statistics and more. Robert Schaub has 1 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Robert Schaub?
Find contact details for 700 million professionals.